Talphera Inc. - Asset Resilience Ratio
Talphera Inc. (TLPH) has an Asset Resilience Ratio of 58.01% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Talphera Inc. carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2024)
This chart shows how Talphera Inc.'s Asset Resilience Ratio has changed over time. See Talphera Inc. net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Talphera Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Talphera Inc. worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $17.83 Million | 58.01% |
| Total Liquid Assets | $17.83 Million | 58.01% |
Asset Resilience Insights
- Very High Liquidity: Talphera Inc. maintains exceptional liquid asset reserves at 58.01% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Talphera Inc. Industry Peers by Asset Resilience Ratio
Compare Talphera Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Talphera Inc. (2008–2024)
The table below shows the annual Asset Resilience Ratio data for Talphera Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $18.24 Million | -- |
| 2023-12-31 | 17.95% | $3.66 Million | $20.39 Million | +16.90pp |
| 2022-12-31 | 1.04% | $495.00K | $47.49 Million | -48.98pp |
| 2021-12-31 | 50.03% | $38.97 Million | $77.89 Million | +26.48pp |
| 2020-12-31 | 23.55% | $15.61 Million | $66.30 Million | -32.77pp |
| 2019-12-31 | 56.32% | $51.45 Million | $91.36 Million | +41.60pp |
| 2018-12-31 | 14.72% | $17.74 Million | $120.53 Million | +4.70pp |
| 2017-12-31 | 10.02% | $7.57 Million | $75.55 Million | +5.68pp |
| 2015-12-31 | 4.34% | $5.54 Million | $127.78 Million | -13.38pp |
| 2014-12-31 | 17.72% | $15.31 Million | $86.42 Million | +3.85pp |
| 2013-12-31 | 13.87% | $15.26 Million | $110.03 Million | -4.47pp |
| 2012-12-31 | 18.34% | $11.83 Million | $64.52 Million | -50.21pp |
| 2011-12-31 | 68.55% | $27.99 Million | $40.84 Million | +59.37pp |
| 2010-12-31 | 9.18% | $627.00K | $6.83 Million | -28.06pp |
| 2009-12-31 | 37.24% | $5.40 Million | $14.49 Million | -25.09pp |
| 2008-12-31 | 62.33% | $14.13 Million | $22.68 Million | -- |
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulat… Read more